CIK 0001645666
KZR Kezar Life Sciences, Inc.
Insider trading from SEC Form 4. Last filing Jul 3, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at Kezar Life Sciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Pichi Luo Chiang SVP, Corporate Controller sell | $1,130 264 shares | -9% | - | |
| 33Weak | Mark C. Schiller Chief Operating Officer sell | $2,401 561 shares | -17% | - |
Transactions
The last 18 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 2, 2025 | Mark C. Schiller Chief Operating Officer | SOpen-market sale Common Stock | -561 | $4.28 | $2,401 | 2,739 | Jul 3, 2025 |
| Jul 2, 2025 | Pichi Luo Chiang SVP, Corporate Controller | SOpen-market sale Common Stock | -264 | $4.28 | $1,130 | 2,711 | Jul 3, 2025 |
| Jul 1, 2025 | Zung Phuong To Chief Development Officer | AGrant or award Employee Stock Option (right to buy)derivative | +7,000 | $0.00 | $0 | 7,000 | Jul 1, 2025 |
| Jun 18, 2025 | Micki Klearman director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 23, 2025 |
| Jun 18, 2025 | Courtney Wallace director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 23, 2025 |
| Jun 18, 2025 | Michael Kauffman director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 23, 2025 |
| Jun 18, 2025 | Elizabeth Garner director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 23, 2025 |
| Jun 18, 2025 | John Franklin Fowler director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 23, 2025 |
| Jun 18, 2025 | Graham K Cooper director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 23, 2025 |
| Jun 18, 2025 | Franklin M Berger director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 23, 2025 |
| Mar 27, 2025 | Marc Belsky Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +4,800 | $0.00 | $0 | 12,000 | Apr 1, 2025 |
| Mar 27, 2025 | Mark C. Schiller Chief Legal Officer | AGrant or award Employee Stock Option (right to buy)derivative | +4,800 | $0.00 | $0 | 12,000 | Apr 1, 2025 |
| Mar 4, 2025 | Marc Belsky Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +7,200 | $0.00 | $0 | 7,200 | Mar 5, 2025 |
| Mar 4, 2025 | Mark C. Schiller Chief Legal Officer | AGrant or award Employee Stock Option (right to buy)derivative | +7,200 | $0.00 | $0 | 7,200 | Mar 5, 2025 |
| Feb 14, 2025 | John Franklin Fowler director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Feb 14, 2025 |
| Jan 9, 2025 | Marc Belsky Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +24,500 | $0.00 | $0 | 24,500 | Jan 13, 2025 |
| Jan 9, 2025 | Christopher J. Kirk CEO | AGrant or award Employee Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Jan 13, 2025 |
| Jan 9, 2025 | Mark C. Schiller Chief Legal Officer | AGrant or award Employee Stock Option (right to buy)derivative | +24,500 | $0.00 | $0 | 24,500 | Jan 13, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Franklin M Bergerdirector
- Marc BelskyChief Financial Officer
- Graham K Cooperdirector
- Pichi Luo ChiangSVP, Corporate Controller
- John Franklin Fowlerdirector
- Elizabeth Garnerdirector
- Michael Kauffmandirector, president, officer
- Christopher J. KirkCEO
- Micki Klearmandirector
- Mark C. SchillerChief Operating Officer
- Zung Phuong ToChief Development Officer
- Courtney Wallacedirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.